tiprankstipranks
Trending News
More News >
Scandion Oncology A/S (SE:SCOL)
:SCOL
Advertisement

Scandion Oncology A/S (SCOL) Price & Analysis

Compare
0 Followers

SCOL Stock Chart & Stats


Financials

SCOL FAQ

What was Scandion Oncology A/S’s price range in the past 12 months?
Scandion Oncology A/S lowest stock price was <$0.01 and its highest was $0.24 in the past 12 months.
    What is Scandion Oncology A/S’s market cap?
    Scandion Oncology A/S’s market cap is $962.52K.
      When is Scandion Oncology A/S’s upcoming earnings report date?
      Scandion Oncology A/S’s upcoming earnings report date is Aug 28, 2025 which is in 32 days.
        How were Scandion Oncology A/S’s earnings last quarter?
        Currently, no data Available
        Is Scandion Oncology A/S overvalued?
        According to Wall Street analysts Scandion Oncology A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Scandion Oncology A/S pay dividends?
          Scandion Oncology A/S does not currently pay dividends.
          What is Scandion Oncology A/S’s EPS estimate?
          Scandion Oncology A/S’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Scandion Oncology A/S have?
          Scandion Oncology A/S has 234,761,410 shares outstanding.
            What happened to Scandion Oncology A/S’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Scandion Oncology A/S?
            Currently, no hedge funds are holding shares in SE:SCOL

            Company Description

            Scandion Oncology A/S

            Scandion Oncology A/S (SCOL) is a biotechnology company specializing in developing innovative treatments to overcome drug resistance in cancer therapy. The company focuses on creating and advancing pharmaceutical solutions that enhance the effectiveness of existing cancer treatments. Scandion Oncology's core product portfolio includes proprietary drug candidates designed to counteract resistance mechanisms in cancer cells, thus improving patient outcomes in oncology sectors.
            Similar Stocks
            Company
            Price & Change
            Follow
            CombiGene AB
            LIDDS AB
            Sprint Bioscience AB
            Xintela AB
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis